I. Sesterhenn

发表

Investigating the distribution of prostate cancer using three-dimensional computer simulation

M. B. Opell, J. Zeng, J. Bauer, 2002, Prostate Cancer and Prostatic Diseases.

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

F. Mostofi, J. Moul, S. Srivastava, 1999, The Journal of urology.

Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Wei Zhang, F. Mostofi, J. Moul, 1999, The Journal of urology.

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

J W Moul, F. Mostofi, J. Moul, 1996, The Journal of urology.

p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.

J. Moul, J. Bauer, I. Sesterhenn, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

S. Srivastava, I. Sesterhenn, I. Sesterhenn, 2008, Oncogene.

Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens

T. Werner, I. Sesterhenn, M. Seifert, 2008, Prostate Cancer and Prostatic Diseases.

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

J. Moul, S. Srivastava, I. Sesterhenn, 1994, Cancer research.

Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

I. Sesterhenn, C. Davis, D. Mcleod, 2008, Journal of Clinical Pathology.

Anterior tumors of the prostate: clinicopathological features and outcomes

I. Sesterhenn, A. Dobi, J. Cullen, 2013, Prostate Cancer and Prostatic Disease.

Improvements in pathologic staging for African‐American men undergoing radical retropubic prostatectomy during the prostate specific antigen era

Laurence R. Paquette, J. Moul, R. Connelly, 2001, Cancer.

Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients

J. Bishoff, F. Mostofi, J. Moul, 2002, Prostate Cancer and Prostatic Diseases.

Allelic loss on chromosome 6Q in primary prostate cancer

F. Mostofi, V. Srikantan, J. Moul, 1999, International journal of cancer.

Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1

Wei Zhang, M. Augustus, V. Srikantan, 2000 .

Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated

M. Augustus, V. Srikantan, J. Moul, 2000 .

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

F. Mostofi, J. Moul, S. Srivastava, 1995, JAMA.

Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer.

J W Moul, J. Moul, I. Sesterhenn, 1995, The Journal of urology.

Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.

J. Moul, I. Sesterhenn, W. Mccarthy, 1994, Cancer research.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2006, Oncogene.

Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.

M. Augustus, V. Srikantan, J. Moul, 2000, The Journal of urology.

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis

F. Mostofi, J. Moul, I. Sesterhenn, 1998, Cancer.

Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.

J. Moul, S. Srivastava, J. Bauer, 1998, Urology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, I. Sesterhenn, 2012, Prostate Cancer and Prostatic Diseases.

Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

F. Mostofi, J. Moul, I. Sesterhenn, 1994, The Journal of urology.

Prostatic intraepithelial neoplasia (PIN): Morphological clinical significance

I. Sesterhenn, I. Sesterhenn, C. Davis, 1992, The Prostate. Supplement.

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, Surgery.

Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.

F. Mostofi, J. Moul, I. Sesterhenn, 2002, International journal of andrology.

Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.

F. Mostofi, J. Moul, I. Sesterhenn, 1997, The Journal of urology.

Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.

J W Moul, J. Moul, I. Sesterhenn, 1994, The Journal of urology.

Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

J. Moul, I. Sesterhenn, W. Mccarthy, 1993, The Journal of urology.

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

J. Moul, J. Bauer, R. Connelly, 1998, The Journal of urology.

[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].

F. Mostofi, J. Moul, I. Sesterhenn, 1999, Der Urologe. Ausg. A.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

S-H Tan, S. Srivastava, I. Sesterhenn, 2010, Prostate Cancer and Prostatic Diseases.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

Z. Szallasi, I. Csabai, G. Klus, 2021, medRxiv.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer

L. Bubendorf, S. Srivastava, I. Sesterhenn, 2014, Prostate Cancer and Prostatic Disease.

PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

W. Zhang, M. Augustus, V. Srikantan, 2000, Cancer research.

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, The Journal of urology.

Histopathological and biological prognostic risk factors in low stage testicular nonseminomatous germ cell tumors

F. Mostofi, J. Moul, I. Sesterhenn, 1999, Der Urologe.

Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.

F. Mostofi, J. Moul, R. Connelly, 2000, The Journal of urology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, S. Srivastava, 2011, Prostate Cancer and Prostatic Diseases.

p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein

W. Zhang, I. Sesterhenn, J. Moul, 2003, Prostate Cancer and Prostatic Diseases.

A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.

J W Moul, J. Moul, S. Srivastava, 2000, Genomics.

Quantitative expression profile of PSGR in prostate cancer

J. Moul, I. Sesterhenn, W. Zhang, 2006, Prostate Cancer and Prostatic Diseases.

Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma.

J. Moul, I. Sesterhenn, D. J. Lewis, 1994, Urology.

Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation.

S K Mun, J. Zeng, W. Zhang, 2001, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer

J. Zeng, W. Zhang, I. Sesterhenn, 2000, Prostate Cancer and Prostatic Diseases.

Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer.

S K Mun, R R Connelly, J. Zeng, 1999, Urology.

Mature, clinical stage I testicular teratoma: retroperitoneal lymphadenetomy or surveillance?

F. Mostofi, J. Moul, I. Sesterhenn, 1997, Der Urologe.

Laser-capture microdissection.

G L Griewe, R Dean, W Zhang, 2001, Methods in molecular medicine.

Prostate biopsy schemes: 3-D visualization-based evaluation.

S K Mun, J. Zeng, W. Zhang, 1999, Studies in health technology and informatics.

Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study.

F. Mostofi, D. Stablein, I. Sesterhenn, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.